Macrophage Cell Therapy 2026 — PatSnap Eureka
Macrophage Cell Therapy: The 2026 Innovation Landscape
From CAR-macrophage engineering to iPSC-derived manufacturing and innate immune checkpoint blockade, macrophage cell therapy has moved from conceptual immunology to active clinical-stage development — with over 606 clinical trials recorded against macrophage-related targets through 2021 alone. This report synthesizes patent and literature evidence across core mechanisms, assignee activity, and emerging directions spanning 2013–2026.
Three Principal Dimensions of Macrophage Cell Therapy
Macrophage cell therapy encompasses three principal technical dimensions: (1) the use of macrophages as directly administered therapeutic cellular agents (adoptive macrophage transfer), (2) the genetic or non-genetic engineering of macrophages to enhance or redirect their anti-tumor function, and (3) pharmacological or biological modulation of endogenous tumor-associated macrophages (TAMs) in the tumor microenvironment (TME).
TAMs are the dominant immune cell population in most solid tumors, constituting up to 50% of the cellular mass in some malignancies and functioning primarily in an immunosuppressive, pro-tumorigenic M2-like state. TAMs promote angiogenesis, extracellular matrix remodeling, tumor cell proliferation, and metastasis, while suppressing cytotoxic T cell activity. The M1/M2 polarization axis — representing classically activated anti-tumor versus alternatively activated pro-tumor phenotypes — forms the conceptual backbone of most therapeutic interventions in this field.
The field has been shaped by convergence across patent analytics and the broader life sciences innovation ecosystem. External bodies including ClinicalTrials.gov and the World Health Organization have tracked the expanding clinical footprint of innate immune therapies as a complement to adaptive immune approaches.
From Foundational Science to Clinical-Stage Development
The field spans roughly 2013–2026 and exhibits a clear maturation arc across three distinct phases.
Early Foundational Phase
Seminal reviews and proof-of-concept studies established the dual role of macrophages in cancer. Work from 2013 documented macrophages as “critical effectors of antibody therapies” and highlighted the phagocytosis-augmenting potential of CD47 blockade. The regenerative medicine framing of macrophage phenotype as a determinant of therapeutic outcome emerged in 2014. Early CAR-macrophage concepts targeting HER2 antigen and CD147 signaling appeared in 2019, marking the translation of CAR technology from T cells to macrophages.
CD47 blockade · Phagocytosis augmentationMid-Stage Development Cluster
The period 2018–2021 saw rapid expansion of both mechanistic understanding and therapeutic modality diversity. By 2021, a global survey counted 606 clinical trials and 143 tested products targeting TAMs, with two-thirds employing macrophage-targeting as combination therapy. iPSC-derived macrophage manufacturing protocols were being optimized for scale-up and cryopreservation. Formal patent filings appeared from the Lundquist Institute (WO 2020) and Seattle Children’s Research Institute in this window.
606 trials · 143 productsEmerging Directions & Recent Filings
The most recent records in this dataset show activity concentrated on: allogeneic MHC-II matched macrophage products (Technische Universitat Dresden, EP 2024); iPSC-derived myeloid progenitor cells with cryopreservable and proliferative capacity (Zhejiang University, CN 2025); engineered stem-cell-derived myeloid cells with synthetic cytokine receptors (Umoja Biopharma, WO 2025); and combination macrophage immunotherapy with cytokines and targeted agents (Whitehead Institute / General Hospital Corporation, WO/US 2023–2026).
Allogeneic · Off-the-shelf · CombinationOncology, Regenerative Medicine & Infectious Disease
Macrophage-targeted strategies span breast cancer, glioblastoma, melanoma, lung cancer, ovarian cancer, osteosarcoma, hematological malignancies (MDS, AML, lymphoma), wound healing, implant biocompatibility, and infectious disease prevention. Engineered macrophages secreting bispecific T cell engagers (BiTEs) targeting EGFRvIII in glioblastoma and macrophage-mediated delivery of Salmonella typhimurium VNP20009 in melanoma represent the breadth of application. See the full PatSnap life sciences coverage for related domains.
Solid tumors · Hematology · Regen medFour Core Clusters Driving Macrophage Cell Therapy Innovation
Patent and literature records reveal four distinct technical clusters, each addressing a different mechanism of macrophage-mediated anti-tumor activity.
Patent Assignee Distribution by Jurisdiction
7 distinct assignees across 5+ jurisdictions; US and WO dominate, with EP, CN, AU, CA, and JP each represented by at least one filing in this dataset.
Reprogramming Strategies by Mechanism
Macrophage reprogramming is the largest and most diverse cluster, spanning TLR agonists, CSF1R inhibitors, epigenetic agents, nanoparticle delivery, and immunostimulatory bacteria.
Key Patent Holders Across 5+ Jurisdictions
Among patent records retrieved in this dataset, 7 distinct patent-holding assignees are identifiable, spanning US, WO, EP, AU, CN, JP, and CA jurisdictions.
| Assignee | Jurisdiction | Year | Status | Focus Area |
|---|---|---|---|---|
| Lundquist Institute / Harbor-UCLA Medical Center | WO, US, US | 2020, 2022, 2024 | Active (US 2024 granted Oct 2024) | Target-primed macrophage adoptive cell therapy |
| Whitehead Institute for Biomedical Research | WO, US, US | 2023, 2025, 2026 | Active / Pending | Combination macrophage immunotherapy + cytokines + targeted agents; high-throughput screening |
| Technische Universitat Dresden | EP | 2024 | Pending | Allogeneic MHC-II matched macrophages for cancer therapy |
CAR-Macrophage Engineering: Highest-Risk, Highest-Reward Platform
The chimeric antigen receptor macrophage (CAR-M) represents the most structurally innovative approach in this dataset. Borrowing from CAR-T cell biology, macrophages are engineered to express tumor-antigen-specific receptors that trigger phagocytosis, cytokine secretion, and TME remodeling upon antigen engagement. CAR-M offers advantages over CAR-T in solid tumors: macrophages naturally traffic to hypoxic tumor cores and can remodel immunosuppressive stroma that excludes T cells.
The earliest CAR-M patent in this dataset targets HER2-expressing breast tumors via CD147 signaling to upregulate matrix metalloproteinases (MMPs) that degrade tumor collagen, promoting T-cell infiltration. iPSC-derived CAR-macrophages (CAR-iMacs) are emerging as a scalable, off-the-shelf variant of primary CAR-M — directly addressing the cell supply constraint that limits primary monocyte-derived approaches.
In glioblastoma, human macrophages engineered to secrete bispecific T cell engagers (BiTEs) targeting EGFRvIII have been documented supporting antigen-dependent T cell responses. Seattle Children’s Research Institute holds an active AU 2024 patent covering genetic engineering of macrophages for TME modification. PatSnap Analytics provides competitive intelligence tools to monitor CAR-M prosecution activity across these assignees. External resources from the NIH and EPO provide complementary patent search infrastructure for freedom-to-operate analysis in this space.
- Naturally traffics to hypoxic solid tumor cores
- Remodels immunosuppressive stroma (MMP upregulation)
- Phagocytosis as primary effector mechanism
- CAR-iMac enables off-the-shelf scalability
- Fewer in number but broadest mechanistic claims
iPSC-Derived Macrophage Manufacturing: The Critical Bottleneck
Protocol variability between differentiation methods generates macrophages with differing immunological properties, creating quality and reproducibility risks for clinical-stage products.
What the Patent Landscape Signals for R&D and IP Strategy
Five directional signals derived from patent filings 2020–2026 for R&D teams, IP strategists, and product developers.
CAR-M: Highest-Risk, Highest-Reward
In this dataset, CAR-macrophage patents are fewer in number than modulation/combination strategies but command the broadest mechanistic claims. R&D teams should monitor whether iPSC-derived CAR-M (CAR-iMac) platforms — which solve the primary cell supply problem — will outpace primary monocyte-derived CAR-M in clinical translation.
CD47/SIRPα Axis Is Already Crowded
Among retrieved records, more than a dozen named CD47-targeting agents are enumerated in combination therapy patents — including TTI-621, TTI-622, AO-176, AK117, HX-009, CC90002. IP strategists should assess freedom-to-operate carefully before investing in additional CD47 blockade claims and consider differentiated innate checkpoint targets (CD24/SIGLEC-10, MHC-I/LILRB1, TAM receptor tyrosine kinases) as alternative prosecution angles.
Five Directional Signals from 2023–2026 Patent Filings
The most recent filings in this dataset reveal where macrophage cell therapy innovation is heading next.
Off-the-Shelf Allogeneic & iPSC-Derived Products
The Zhejiang University CN 2025 filing and Umoja Biopharma WO 2025 filing both target the manufacturing bottleneck: producing cryopreservable, rapidly proliferating macrophage progenitors. The Umoja filing introduces synthetic cytokine receptors responsive to non-physiological ligands — enabling controlled in vivo macrophage expansion post-infusion without dependence on endogenous cytokine signaling. Assignees who establish proprietary, validated, cryopreservable progenitor platforms will hold durable manufacturing IP advantages. See PatSnap Analytics for competitive monitoring tools.
Zhejiang Univ. CN 2025 · Umoja WO 2025Allogeneic MHC-II Matched Macrophage Therapy
Technische Universitat Dresden’s EP 2024 patent introduces a conceptually distinct approach: allogeneic macrophages selected for shared MHC-II haplotype with the recipient patient, enabling antigen presentation to host CD4+ T cells against tumor neoantigens. This positions macrophages as antigen-presenting intermediaries between innate and adaptive immunity in an allogeneic context — a distinctive approach not seen elsewhere in this dataset.
Dresden EP 2024 · MHC-II matchedCombination Macrophage Immunotherapy Platforms
Multiple 2023–2026 filings from Whitehead Institute and General Hospital Corporation claim methods of combining macrophage immune checkpoint inhibitors (anti-CD47, anti-SIRPα, anti-EGFR, CD40 agonists) with cytokines or molecularly targeted agents. The breadth of CD47/SIRPα axis inhibitors enumerated — including TTI-621, TTI-622, AO-176, AK117, HX-009, CC90002 — signals a competitive pipeline consolidating around this checkpoint. PatSnap customers in oncology use these signals for competitive intelligence.
Whitehead Inst. US 2026 · GHC US 2025High-Throughput Screening for Macrophage Function Modulators
A 2025 Whitehead Institute US filing claims a high-throughput assay for identifying agents that modulate macrophage-mediated cytotoxicity, signaling the build-out of discovery infrastructure to feed the macrophage immunotherapy pipeline systematically. Separately, Genentech’s WO and JP 2024 filings on macrophage biomarkers for lymphoma diagnosis indicate the field is maturing toward companion diagnostics — using macrophage gene expression signatures to identify which patients will respond to macrophage-modulating therapies. Access the full PatSnap API for programmatic data access.
Whitehead US 2025 · Genentech WO 2024Macrophage Cell Therapy — key questions answered
Macrophage cell therapy encompasses strategies that deploy, engineer, or reprogram macrophages as direct therapeutic agents or combination partners in oncology and regenerative medicine, including CAR-macrophage engineering, iPSC-derived cell manufacturing, and innate immune checkpoint biology.
Over 606 clinical trials were recorded against macrophage-related targets through 2021, with 143 tested products, and two-thirds employing macrophage-targeting as combination therapy.
TAMs are the dominant immune cell population in most solid tumors, constituting up to 50% of the cellular mass in some malignancies. They function primarily in an immunosuppressive, pro-tumorigenic M2-like state, promoting angiogenesis, extracellular matrix remodeling, tumor cell proliferation, and metastasis.
CAR-macrophages are engineered with tumor-antigen-targeting chimeric antigen receptors to enable phagocytosis, cytokine secretion, and TME remodeling upon antigen engagement. CAR-M offers advantages over CAR-T in solid tumors because macrophages naturally traffic to hypoxic tumor cores and can remodel immunosuppressive stroma.
CD47 is a “don’t eat me” signal on tumor cells that inhibits macrophage-mediated phagocytosis. Blocking the CD47/SIRPα interaction enhances macrophage phagocytosis of tumor cells. Multiple clinical-stage agents target this axis including TTI-621, TTI-622, AK117, CC90002, and SRF231.
Primary macrophages cannot be expanded at clinical scale. iPSC differentiation platforms resolve this by enabling theoretically unlimited production of genetically defined macrophages from a single clonal source, addressing the fundamental supply constraint in macrophage cell therapy.
PatSnap Eureka searches patents and research literature to answer instantly.